ライフサイエンスコーパス: dominant-negative mutant

1 teasome inhibitor MG132 and a Cullin5 (Cul5) dominant negative mutant.

2 d 293 cells stably expressing the PERK-K618A dominant negative mutant.

3 allele expressed, although not as a classic dominant-negative mutant.

4 steoclastogenesis was also inhibited by Dvl2 dominant negative mutants.

5 small) G-proteins yield nucleotide-depleted, dominant-negative mutants.

6 , and JNK were assessed using inhibitors and dominant-negative mutants.

7 n lesions, and we also examine phenotypes of dominant-negative mutants.

8 LN3 function by expression of a channel-dead dominant negative mutant (458DD/KK) or by knockdown of e

9 ion; however, inactivating SHP2 and p38 with dominant negative mutants abrogated CXCL8 induction.

10 f that PI3K by either chemical inhibitors or dominant-negative mutants abrogated the inhibitory effec

11 ase and Akt by either chemical inhibitors or dominant-negative mutants abrogated the RNS60-mediated u

12 a-arrestin using either siRNA knockdown or a dominant negative mutant abrogates the enhanced CXCL12-d

13 and Cdc42 using pharmacologic inhibitors and dominant negative mutants also inhibited the fMLF-induce

14 1b and ZmETR2b that is present in the etr1-1 dominant negative mutant and expressed each protein in A

15 Using dominant negative mutants and rescue experiments, we dem

16 -Cys (DHHC) zinc finger protein; (ii) a GODZ dominant-negative mutant and an inhibitor of palmitoylat

17 Kinase-dead PRK2 acts as a dominant-negative mutant and prevents apical junction fo

18 In contrast, both the dominant-negative mutant and the phosphoinositide lipids

19 ereas AP-1 activation decreased in both MSK1 dominant-negative mutants and in MSK1 knockdown cells.

20 ection of IL-6 promoter reporter constructs, dominant negative mutants, and electromobility shift ass

21 Using inhibitory drugs, dominant negative mutants, and small interfering RNAs (s

22 Here we establish, using shRNAs, a dominant-negative mutant, and a pharmacologic inhibitor,

23 factor 6 (ARF6) small interfering RNA, ARF6 dominant-negative mutant ARF6(T27N), and ARF6 activation

24 ockade of Egr-1 via forced expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H

25 on via adenovirus-mediated expression of its dominant-negative mutant attenuated 15(S)-HETE-induced H

26 EB activation by pharmacologic inhibition or dominant negative mutants blocks the 5-LO-dependent elev

27 p1 activation by pharmacologic inhibition or dominant-negative mutant blocks the 12/15-LO-dependent e

28 holinos or a naturally occurring human BMP15 dominant-negative mutant (BMP15-Y235C) leads to embryos

29 red in the basilar artery of mice expressing dominant-negative mutants, but not in mice expressing wi

30 erestingly, overexpression of the Ubc9 trans-dominant-negative mutant C93A, which is a defective E2-S

31 In experiments using dominant negative mutants, cdc42 activity was required f

32 yonic fibroblasts (MEFs) and overexpressed a dominant-negative mutant CKIepsilon (DN-CKIepsilon) in t

33 Moreover, CUL2 and UBE2M dominant negative mutants competitively inhibited the BI

34 Jam-B and Jam-C using antibodies, siRNA, or dominant-negative mutants completely interferes with lum

35 ng beta-catenin signaling by transfection of dominant-negative mutant constructs to either T-cell fac

36 -type CREB promoted SnoN expression, whereas dominant negative mutant CREB abrogated SnoN induction b

37 BAF57 RNAi and BAF57 dominant negative mutants defective in CaM binding simil

38 Moreover, a rio1 dominant-negative mutant defective in ATP hydrolysis ind

39 dialysis and molecular biology in a putative dominant-negative mutant DISC1 transgenic model.

40 ochondrial fission through expression of the dominant-negative mutant DLP1-K38A eliminated this dynam

41 t, MSK1 COOH terminal or NH(2) terminal dead dominant negative mutants dramatically suppressed cell t

42 of TSHR internalization, and expression of a dominant-negative mutant dynamin, which inhibited intern

43 elta-small interfering RNA, or with PKCdelta dominant-negative mutant effectively increased a number

44 Blocking TCF-4 activity with a dominant-negative mutant enhanced HIV replication by thr

45 Stable expression of a dominant-negative mutant ERK eliminated the effects of i

46 riggered by canonical Wnt ligands, LRP6, and dominant negative mutants for Axin and GSK3, indicating

47 orrected by intramuscular gene transfer of a dominant negative mutant form of p75(NTR).

48 n muscle-specific transgenic mice expressing dominant-negative mutant form of AMPK or in AdipoR1-knoc

49 not its mutant, or ectopic expression of the dominant-negative mutant form of ATF-6 protected cells f

50 teins mitofusin 1 or 2 or with Drp1(K38A), a dominant-negative mutant form of Drp1, increased the per

51 By using cell lines stably expressing a dominant-negative mutant form of VPS4, we also show that

52 /2, and mitochondrial complex II; as well as dominant negative mutant forms of IkappaBalpha and NOX4

53 the role of Sar1p in pexophagy by expressing dominant-negative mutant forms of Sar1p in Pichia pastor

54 We used dominant negative mutant, genetic knockout, gene knockdo

55 Overexpression of STAT3 dominant-negative mutants greatly diminishes this SOCS-3

56 R2 using an inhibitor, short hairpin RNA and dominant-negative mutant HER2 abolished IR-induced activ

57 nfected with GFP (control), hERG (I(Kr)), or dominant negative mutant hERG G628S.

58 Expression of dominant negative mutant HNF-1beta or kidney-specific in

59 Expression of dominant-negative mutant HNF-1beta in mIMCD3 cells produ

60 ice and in renal epithelial cells expressing dominant-negative mutant HNF-1beta.

61 t mice and renal epithelial cells expressing dominant-negative mutant HNF-1beta.

62 A dominant-negative mutant, HRES-1/Rab4(S27N) had reduced

63 ith endothelium-targeted overexpression of a dominant-negative mutant human insulin receptor (ESMIRO)

64 ng B16/OVA cells engineered to overexpress a dominant negative mutant IFN-gamma receptor (B16/OVA/DNM

65 e to IFN-gamma" (MIIG) mice, which express a dominant negative mutant IFN-gamma receptor in CD68+ cel

66 the IkappaB kinase inhibitor BAY11-7085 and dominant-negative mutant IkappaBalphaM inhibited NF-kapp

67 ce showed that the CDK2-DN protein acts as a dominant negative mutant in mature T cells as expected,

68 d how CHIP recognizes Hsp/c70, we utilized a dominant negative mutant in which loss of a conserved pr

69 terfering with BVES function by expressing a dominant-negative mutant in human corneal epithelial cel

70 on via gene silencing or overexpression of a dominant negative mutant increased human keratinocyte ce

71 Conversely, overexpression of a STX6 dominant-negative mutant increases CFTR.

72 ting recruitment of Vinculin by expressing a dominant-negative mutant increases the rate of furrow in

73 Coro1A(E26K) is not a dominant-negative mutant, indicating that its pathologic

74 knockdown of alphaSNAP or expression of its dominant negative mutant induced epithelial cell apoptos

75 n of PKMzeta in mPFC by expressing a PKMzeta dominant-negative mutant induced depressive-like behavio

76 own, knock-out, and enforced expression of a dominant-negative mutant inhibited rictor ubiquitination

77 ase-defective DHX33 mutant (K94R) acted as a dominant negative mutant, inhibiting endogenous rRNA syn

78 aB-specific inhibitor or overexpression of a dominant negative mutant inhibitory NF-kappaB (IkappaBal

79 Blockade of ATR with a dominant-negative mutant inhibits cisplatin-induced p53

80 was severely impaired in cells expressing a dominant-negative mutant IRF3 and completely abrogated i

81 induced by Sgo1 depletion or expression of a dominant negative mutant is suppressed by ectopic expres

82 Analysis of dominant negative mutants is consistent with dimerizatio

83 g a missense R174Q mutation, which acts as a dominant-negative mutant, is associated with thrombocyto

84 ediated engulfment, we used a combination of dominant-negative mutants, knockdown of specific signali

85 , we overexpressed beta-arrestin2-(1-320), a dominant negative mutant known to block receptor endocyt

86 lize with GPER, and expression of arrestin-2 dominant-negative mutants lacking clathrin- or beta-adap

87 -positive (LdRab5a:Q93L and LdRab5b:Q80L) or dominant-negative mutants (LdRab5a:N146I and LdRab5b:N13

88 small interfering RNA or by expression of a dominant negative mutant led to inhibition of wound-indu

89 d stress in OsCAF1B overexpression lines and dominant-negative mutant lines.

90 The second, trlR, is a nonfunctional, dominant-negative mutant located in an operon that is in

91 NFAT-dependent manner and pharmacological or dominant negative mutant-mediated blockade of PKN1 funct

92 Dominant negative mutant-mediated interference of RhoA a

93 Dominant-negative mutant-mediated interference of STAT-5

94 carrier (MPC) isoforms or expression of the dominant negative mutant MPC1(R97W) resulted in increase

95 Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1, here we demonstrate th

96 heavy chain depletion or expression of AP180 dominant-negative mutant not only disrupted clathrin-reg

97 B1 was abrogated by the co-transduction of a dominant negative mutant of AMPK.

98 Kalpha1 subunit, whereas the expression of a dominant negative mutant of AMPKalpha1 or ablation of AM

99 ll proliferation as does overexpression of a dominant negative mutant of BAP1.

100 Gene transfer of dominant negative mutant of BiP in the lung endothelium

101 harmacological inhibitor and expression of a dominant negative mutant of c-Abl, we show an essential

102 olog (Cdc42) because cooverexpression of the dominant negative mutant of Cdc42 [namely, Cdc42-T17N (v

103 firmed by conditional expression of TAM67, a dominant negative mutant of cJun.

104 CRAG knockdown by siRNA or expression of a dominant negative mutant of CRAG significantly attenuate

105 f HeLa cells with MLN4924 or expression of a dominant negative mutant of cullin1 inhibited the Vpu-me

106 ace OAT1 increases in cells transfected with dominant negative mutant of dynamin-2, a maneuver blocki

107 Overexpression of a dominant negative mutant of EhRab35 reduced phagocytic c

108 r pathways due to transgenic expression of a dominant negative mutant of Fas-associated death domain

109 In addition, we have identified a dominant negative mutant of GAPDH, which inhibits RNA sy

110 rotein expression, while the expression of a dominant negative mutant of GATA-3 or a GATA-3 shRNA con

111 Here we report that overexpression of dominant negative mutant of GRK5 (dnGRK5) in a cholinerg

112 unoprecipitated with wild-type Hsc70, with a dominant negative mutant of Hsc70, and with the minimal

113 ith cardiomyocyte-restricted expression of a dominant negative mutant of IkappaBalpha (IkappaBalpha(S

114 o induce NRF2 because either expression of a dominant negative mutant of IkappaBalpha that leads to N

115 Indeed, a dominant negative mutant of KCNQ4_v1 cripples the curren

116 ylation of p38, and that overexpression of a dominant negative mutant of MKP-1 does the opposite.

117 Selective knockdown of MyD88 by a dominant negative mutant of MyD88 or selective siRNA als

118 and functional role of omega, we isolated a dominant negative mutant of omega (omega6), which is pre

119 Expression of a dominant negative mutant of p53 causes significant rever

120 horylation of PKCzeta can be suppressed by a dominant negative mutant of PDK1.

121 lly, EEA1 down-regulation or expression of a dominant negative mutant of PKC-alpha blunts Ang II-indu

122 of Rab1), and GFP-LdRab1:S22N (a GDP-locked dominant negative mutant of Rab1).

123 f rLCMV-LASVGP was only mildly affected by a dominant negative mutant of Rab5 and was independent of

124 A dominant negative mutant of Rac1 abolished tRA-induced p

125 ated gene transfer, that overexpression of a dominant negative mutant of Rac1 or local knockout of Ra

126 The use of the dominant negative mutant of Ras has been crucial in eluc

127 Moreover, a dominant negative mutant of SCG10 (Cys 22,Cys 24-->Ala 2

128 mic reticulum-derived vesicle formation by a dominant negative mutant of small GTPase Sar1 had no det

129 Overexpression of a dominant negative mutant of TAK1 or knockdown of TAK1 in

130 n of cyt b(558), which could be blocked by a dominant negative mutant of the clathrin-coated pit-asso

131 iving adenovirus that encoded KCNH2-G628S, a dominant negative mutant of the I(Kr) potassium channel

132 Expression of a dominant negative mutant of these factors in transgenic

133 on of the gain-of-function G019S mutation or dominant negative mutant of TRPC6) results in the misloc

134 Transfection of cells with the dominant negative mutant of ubiquitin Ub-K48R, which pre

135 ited by the proteasome inhibitor MG132 and a dominant negative mutant of ubiquitin, K6W-Ub, indicatin

136 express wild-type, constitutively active, or dominant negative mutant of various Rab GTPases.

137 ag-ESCRT-I or -II fusions was inhibited by a dominant negative mutant of Vps4 ATPase similar to wild

138 same way as did reduced ARAP2 expression and dominant negative mutants of Arf6 and Rac1 reversed the

139 and identified constitutively activated and dominant negative mutants of DLC-1.

140 n of K(+) from the cells, or transfection of dominant negative mutants of dynamin-2 or Eps15 into the

141 R2, and ERS2, are present in Arabidopsis and dominant negative mutants of each that confer ethylene i

142 , while inhibiting Cdc42 signaling by either dominant negative mutants of FGD1 or Cdc42 suppressed os

143 is stimulated by FLASH and inhibited by both dominant negative mutants of FLASH and anti-FLASH antibo

144 Overexpression of dominant negative mutants of GRAF1/2, WDR44, and MICAL1

145 Furthermore, the use of dominant negative mutants of histone H3 revealed that Co

146 We further showed that dominant negative mutants of Hsc70 were also recruited t

147 However, Dynasore (dynamin inhibitor), the dominant negative mutants of NM23-H1 (dynamin activator)

148 on and was reduced in cells transfected with dominant negative mutants of p115-Rho GEF or RhoA, and b

149 ologs in a yeast model host or expression of dominant negative mutants of plant Rab5 greatly decrease

150 ficient or phosphorylation-defective (Y402F) dominant negative mutants of Pyk2.

151 hanced activity is abrogated by kinase-dead, dominant negative mutants of Raf-1 (Raf-1-K375M) and Mek

152 The identification of dominant negative mutants of Vif presents exciting possi

153 In this study, we identified dominant negative mutants of Vif that interfered with th

154 We fused a dominant-negative mutant of 53BP1, DN1S, to Cas9 nucleas

155 terfering RNA, an AKT inhibitor as well as a dominant-negative mutant of AKT1, blocks this activation

156 st SB431542 and overexpression of Smad7 or a dominant-negative mutant of Alk-5.

157 tablished stable cell lines by introducing a dominant-negative mutant of AMPK alpha1 subunit or its s

158 brogated by small hairpin RNA (shRNA) or the dominant-negative mutant of AMPK alpha1 subunit.

159 ological inhibition of AMPK, expression of a dominant-negative mutant of AMPKalpha1, and P2Y receptor

160 Expression of a ceramide-binding but dominant-negative mutant of aPKC suppresses ciliogenesis

161 2 target gene expression via expression of a dominant-negative mutant of ATF2 or expression of an ATF

162 In the presence of a dominant-negative mutant of beta-actin, the repositionin

163 e is shortened by betaTrCP but extended by a dominant-negative mutant of betaTrCP, by RSK1/S6K1 inhib

164 B) activation] or overexpression of TAM67 (a dominant-negative mutant of c-Jun) dramatically inhibite

165 e also found in transgenic mice expressing a dominant-negative mutant of Cadm4 lacking its cytoplasmi

166 In addition, overexpression of a dominant-negative mutant of caveolin 1 did not have any

167 By using a dominant-negative mutant of Cul5 and silencing Cul5 expr

168 p junction coupling by viral expression of a dominant-negative mutant of Cx26 (also known as Gjb2) or

169 Inhibition of DNM2 GTPase activity and dominant-negative mutant of DNM2 showed a functional rol

170 iral-mediated gene transfer to overexpress a dominant-negative mutant of DVL in NAc, or by using a ph

171 pressor of IkappaBalpha, or FAK, and using a dominant-negative mutant of FAK (FRNK), blocks melanoma

172 Expression of dominant-negative mutant of Fas-associated death domain

173 h decreased cell viability in MDM, whereas a dominant-negative mutant of FOXO3a or small interfering

174 Accordingly, expressing a dominant-negative mutant of GAB1, which reduced its inte

175 GSK3beta in the NAc, while overexpressing a dominant-negative mutant of GSK3beta promoted resilience

176 c mice with cardiac-specific expression of a dominant-negative mutant of IkappaB alpha (IkappaB alpha

177 arkedly impaired in C2C12 cells expressing a dominant-negative mutant of IkappaBalpha.

178 ANK, the dominant-negative mutant of ILK, also blocked the phosph

179 to express either a constitutively active or dominant-negative mutant of Inhibitor of kappa B kinase

180 g, which could be rescued by expression of a dominant-negative mutant of Lef1 that interferes with be

181 cretase inhibitor (GSI) or transduction of a dominant-negative mutant of MAML1.

182 Transfection of a dominant-negative mutant of MEF2C significantly inhibite

183 Expressing a dominant-negative mutant of NF-YA, a key transcriptional

184 ly, NRF2 overexpression inhibited, whereas a dominant-negative mutant of NRF2 exacerbated RAC1-depend

185 Accordingly, a dominant-negative mutant of p21(rac), but not p21(ras),

186 activation of NF-kappaB by Deltap21(ras), a dominant-negative mutant of p21(ras), supported the invo

187 specific expression of Pim-1 (Pim-WT) or the dominant-negative mutant of Pim-1 (Pim-DN) in transgenic

188 Moreover, a dominant-negative mutant of PKC-delta blocked albumin-in

189 urther confirmed by the forced expression of dominant-negative mutant of protein kinase C delta.

190 This effect was inhibited by a dominant-negative mutant of Rab11, suggesting that CIN85

191 A dominant-negative mutant of Rab8a strongly binds to the

192 and NF-kappaB, as well as transfection of a dominant-negative mutant of Ras (RasN17), significantly

193 differentiation by targeting expression of a dominant-negative mutant of retinoic acid receptor alpha

194 A dominant-negative mutant of RhoA also blocked U46619-ind

195 se observations suggest that D477G acts as a dominant-negative mutant of RPE65 that delays chromophor

196 r N',N'-dimethylsphingosine or expression of dominant-negative mutant of SK1(G82D) or specific small

197 Overexpression of a dominant-negative mutant of SNX17 and RNA interference k

198 addition, adenovirus-mediated expression of dominant-negative mutant of Src blocked 15(S)-HETE's eff

199 nt for the transformation process, because a dominant-negative mutant of Stat3 interferes with PI3K-i

200 n the transcriptional level, expression of a dominant-negative mutant of the basic region leucine zip

201 hageal adenocarcinoma cells of beta2SP and a dominant-negative mutant of the Notch coactivator master

202 f30-depleted cells or cells overexpressing a dominant-negative mutant of the protein results from abe

203 th cone morphology, expression of a putative dominant-negative mutant of the receptor, CS-HmLAR2, lea

204 Moreover, we show that a dominant-negative mutant of the ternary complex factor (

205 Consistent with this effect, expressing a dominant-negative mutant of ULK1 or ATG4b or a ULK1-targ

206 the erythroid cell-specific expression of a dominant-negative mutant of USF, A-USF, in transgenic mi

207 In contrast, dominant-negative mutants of Akt and pharmacologic inhib

208 Constitutively active and dominant-negative mutants of AMPK and Akt were used to e

209 Here, we show that dominant-negative mutants of ATL1 in PC-12 cells inhibit

210 First, dominant-negative mutants of CNOT7 and CNOT8 reduced PUM

211 Using dominant-negative mutants of dynamin-2 (dyn2K44A) and ca

212 Furthermore, dominant-negative mutants of either Cullin1 or Cullin5,

213 Coexpression of dominant-negative mutants of IkappaB kinase alpha (IKKal

214 atory effect was inhibited, however, by both dominant-negative mutants of Mek2 (Mek2-K101A) and K-Ras

215 We reported previously that dominant-negative mutants of one of the telomeric protei

216 Dominant-negative mutants of PAX5 and IKZF1, however, re

217 elial function in transgenic mice expressing dominant-negative mutants of PPARgamma under the control

218 endosomes are disrupted by the expression of dominant-negative mutants of Rab5 and Rab11.

219 The dominant-negative mutants of RhoA and RhoC, but not Rac1

220 In contrast, dominant-negative mutants of SPTLC1 inhibited ABCA1 effl

221 generally cause pro-[PSI(+)] effects, since dominant-negative mutants of Ssa1 or Ssa2 cure [PSI(+)],

222 ology and Golgi movement through analyses of dominant-negative mutants of the putative GTPase domain

223 Expression of specific dominant-negative mutants of the Xenopus Kir6.1 pore sub

224 on of TNF-induced superoxide generation with dominant-negative mutants of TRADD or Rac1, as well as k

225 ignificance of signaling was confirmed using dominant negative mutants or pharmacological inhibitors.

226 and were prevented by TRPC1, -C4, and Orai1 dominant negative mutants or TRPC5 siRNA.

227 Inhibition of TRF2, either by a dominant-negative mutant or by RNA interference, dissoci

228 eorganization of VIFs caused by expressing a dominant-negative mutant or by silencing vimentin with s

229 When vimentin organization is disrupted by a dominant-negative mutant or by silencing, there is a los

230 kyrin G function either by over-expressing a dominant-negative mutant or by siRNA knockdown decreases

231 Inhibition of PKCdelta by a dominant-negative mutant or by targeted gene deletion bl

232 hibiting endogenous chaperone molecules by a dominant-negative mutant or chemical inhibitors recapitu

233 Inactivation of HIF by expression of a HIF dominant-negative mutant or deletion of HIF-1alpha by RN

234 ion of Merlin transport by expression of the dominant-negative mutant or depletion of kinesin-1 resul

235 Inhibition of Chk2 by a dominant-negative mutant or gene deficiency attenuates c

236 cells, we show that FOXO1 inhibition using a dominant-negative mutant or lentivirus-encoded small hai

237 ical conditions in vivo, blocking it using a dominant-negative mutant or lithium chloride prevented m

238 nduced phosphorylation was abolished in MSK1 dominant-negative mutant or MSK1 knockdown cells.

239 interaction of UL20 with GODZ, using a GODZ dominant-negative mutant or possibly GODZ shRNA, should

240 cilia and inhibition of Rab11 function by a dominant-negative mutant or RNA interference blocks prim

241 ession of endogenous beta-TrCP function by a dominant-negative mutant or small interfering RNA-mediat

242 Disruption of RalA function by dominant-negative mutants or siRNA-mediated knockdown at

243 of Src, PLD1, or PKCgamma via pharmacologic, dominant negative mutant, or siRNA approaches significan

244 Inhibition of PLD2 by shRNA, a dominant-negative mutant, or a small molecule inhibitor

245 ession of a Gbetagamma sequestrant, a GRK2/3 dominant-negative mutant, or siRNA-mediated knockdown in

246 periments using PTP1B(-/-) fibroblast lines, dominant-negative mutants, or small interfering RNAs ind

247 1 shRNA (DPSC/ORAI1sh) or overexpressed with dominant negative mutant ORAI1(E106Q) (DPSC/E106Q) exhib

248 sed on the effects of expression of either a dominant-negative mutant Orai3 that is an essential comp

249 Moreover, expression of a dominant-negative mutant Orai3, either alone or in cells

250 en, California) gene switch technology and a dominant-negative mutant polypeptide of herpes simplex v

251 Also, this dominant negative mutant prevented accumulation of CerS6

252 Using a dominant-negative mutant protein of the methyl-directed

253 The expression of Rab20 or the dominant-negative mutant Rab20T19N does not affect trans

254 tively active Rab8, and coexpression of this dominant-negative mutant Rab8 blocks trafficking to the

255 Expression of the dominant-negative mutant Rac1N17 inhibits the cortical F

256 The dominant negative mutant recombinant SPLUNC1 (p.G22E) sh

257 versely, inhibition of STAT3 using siRNAs or dominant negative mutants reduced KIM-1 expression in a

258 levels of Cdc42-GTP, transfection of a Cdc42 dominant-negative mutant reduced cell growth and migrati

259 er-luciferase reporter constructs, whereas a dominant-negative mutant reduces expression.

260 state that can be induced by the presence of dominant-negative mutant repressors (Vir).

261 ls through RNA interference or expression of dominant-negative mutants results in differentiation.

262 olerance in HSFA6b-null, overexpression, and dominant negative mutants revealed that HSFA6b is a posi

263 phosphorylation and was reduced by the RhoA dominant negative mutant RhoA(T19N) and Rho and myosin l

264 smooth muscle contraction by expressing the dominant negative mutants RhoA T19N and cdc42 T17N, and

265 ion by adenovirus-mediated expression of its dominant negative mutant, significantly attenuated 14,15

266 e inhibition of endogenous H-Ras by specific dominant-negative mutant/siRNA markedly ablated the HO-1

267 rsely regulated by NF2, through the use of a dominant-negative mutant, small hairpin RNA or a small m

268 orced expression of constitutively active or dominant-negative mutant STAT5A in mouse brain ECs, we f

269 Using protein kinase inhibitors, dominant negative mutant studies and mouse embryonic fib

270 on via adenovirus-mediated expression of its dominant-negative mutant suppressed 15(S)-HETE-induced H

271 r blocking their signaling by overexpressing dominant negative mutants suppresses netrin-1-induced gr

272 pseudosubstrate inhibitor, or its siRNA, or dominant negative mutants suppresses the cross-desensiti

273 Moreover, expression of dominant-negative mutant Syt1 which inhibits Ca(2+)-depe

274 and elevated thyroid hormone levels due to a dominant-negative mutant T(3) receptor (TRbeta(PV)) that

275 inactivation of Cdc42 by overexpressing its dominant-negative mutant T17N in Sertoli cell epithelium

276 tive form of the cJun proto-oncogene, a cJun dominant negative mutant (Tam67), blocks AP-1 transcript

277 ling assay, we showed that the expression of dominant-negative mutant TAp73 expression plasmid (p73DD

278 Dominant-negative mutants targeting p38alpha and p38beta

279 Transgenic mice harboring the dominant-negative mutant TGF-beta type II receptor (DNTG

280 2 mutations detected so far are recessive, a dominant negative mutant that affects GlyT2 trafficking

281 he tumor-related lncRNA HOTAIR, comprising a dominant negative mutant that was computationally design

282 MLL fusions function as dominant negative mutants that abrogate the ATR-mediated

283 xpression of the Spc110 C terminus acts as a dominant-negative mutant that titrates endogenous Spc110

284 Mice harbouring a dominant-negative mutant thyroid hormone receptor beta (

285 interfering RNA (siRNA) duplexes and ac-Cbl dominant negative mutant to show that c-Cbl is critical

286 pecific for Sdc1 and Sdc4 recognition act as dominant negative mutants to block cell spreading or cel

287 TEN lipid and protein phosphatase may act as dominant-negative mutants to suppress endogenous PTEN an

288 s TTP and BRF proteins, or overexpression of dominant-negative mutant TTP proteins, impairs the local

289 Surprisingly, the dominant negative mutant Ubc9 (Ubc9-DN) also causes the

290 ession of UBE2L3 and LUBAC, but abolished by dominant-negative mutant UBE2L3 (C86S), or UBE2L3 silenc

291 Like the previously isolated dominant-negative mutants, unc-108 loss-of-function muta

292 we demonstrate that the overexpression of a dominant-negative mutant variant of human PROM1 (i.e. mu

293 gether with pharmacological agents, RNAi and dominant negative mutants, we have demonstrated that tar

294 acological inhibitors, RNA interference, and dominant-negative mutants, we define the mechanisms invo

295 Using inhibitors and dominant-negative mutants, we found that eIF4A is requir

296 Short hairpin RNA and dominant-negative mutants were used to inhibit activitie

297 Short hairpin RNA and dominant-negative mutants were used to inhibit activity

298 This dominant-negative mutant, which is deficient in GTP bind

299 TRalpha1PV is a dominant negative mutant with a frameshift mutation in t

300 eversed by activated AKT and reproduced by a dominant negative mutant, wortmannin, or PTEN.